Ultragenyx Pharmaceutical

Ultragenyx is a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases.

Industries

Biotechnology

Headquarters

Novato, United States

Stage

Post IPO Equity

Employees

501-1,000

Links

Org chart

Emil D. Kakkis

CEO & President

Collapse

Dennis Huang

Chief Technical Operations Officer & EVP, Gene Therapy Research & Development

Erik Harris

EVP, Chief Commercial Officer

Ernie Meyer

EVP, Chief Human Resources Officer

John Pinion

EVP, Translational Sciences & Chief Quality Operations Officer

Eric Crombez

Chief Medical Officer & EVP

Thomas Kassberg

EVP, Chief Business Officer

Karah Parschauer

EVP, Chief Legal Officer

Teams

View all

CEO and Executive Team

7 members

Leadership Team

7 members

Board of Directors

8 members

Discover similar companies

NeoGenomics

Fort Myers, United States · Post IPO Equity

Sema4

Stamford, United States · Post IPO Equity

Legend Biotech

Piscataway, United States · Post IPO Equity

Atara Biotherapeutics

South San Francisco, United States · Post IPO Equity

Aimmune Therapeutics

Brisbane, United States · Post IPO Equity

Biohaven Pharmaceuticals

New Haven, United States · Post IPO Equity

Sage Therapeutics

Cambridge, United States · Post IPO Equity

Sarepta Therapeutics

Cambridge, United States · Post IPO Equity

Insmed

Bridgewater, United States · Post IPO Equity

Veracyte

South San Francisco, United States · Post IPO Equity

Standard BioTools

South San Francisco, United States · Post IPO Equity

NanoString

Seattle, United States · Post IPO Equity

The Org
helps you hire
great candidates

It takes less than ten minutes to set up your company page.
It’s free to use - try it out today.